Immunovant (IMVT) News Today $15.47 +0.04 (+0.26%) Closing price 04:00 PM EasternExtended Trading$14.62 -0.86 (-5.53%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period 20,573 Shares in Immunovant, Inc. (NASDAQ:IMVT) Purchased by F M Investments LLCF M Investments LLC bought a new stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 20,573 shares of the company's stock, valued at approximately $510,000. Several other laApril 14 at 5:41 AM | marketbeat.com29,233 Shares in Immunovant, Inc. (NASDAQ:IMVT) Purchased by ExodusPoint Capital Management LPExodusPoint Capital Management LP acquired a new stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 29,233 shares of the company's stock, valued at approxApril 14 at 4:04 AM | marketbeat.comFmr LLC Increases Stock Position in Immunovant, Inc. (NASDAQ:IMVT)Fmr LLC grew its position in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 4.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 13,097,915 shares of the company's stock after purchasing an additional 560,344 shares during the qApril 13 at 5:25 AM | marketbeat.comInsider Selling: Immunovant, Inc. (NASDAQ:IMVT) CEO Sells 28,094 Shares of StockApril 12 at 5:37 AM | insidertrades.comImmunovant (NASDAQ:IMVT) Shares Gap Down - Should You Sell?Immunovant (NASDAQ:IMVT) Shares Gap Down - Here's What HappenedApril 11, 2025 | marketbeat.comJPMorgan Chase & Co. Has $28.57 Million Holdings in Immunovant, Inc. (NASDAQ:IMVT)JPMorgan Chase & Co. boosted its stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 405.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,153,338 shares of the company's stock afApril 10, 2025 | marketbeat.comIs Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires?April 9, 2025 | finance.yahoo.comImmunovant (NASDAQ:IMVT) Sets New 12-Month Low - What's Next?Immunovant (NASDAQ:IMVT) Reaches New 1-Year Low - Here's What HappenedApril 9, 2025 | marketbeat.comADAR1 Capital Management LLC Sells 354,429 Shares of Immunovant, Inc. (NASDAQ:IMVT)ADAR1 Capital Management LLC reduced its stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 31.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 787,478 shares of the comApril 9, 2025 | marketbeat.comNorges Bank Purchases Shares of 637,947 Immunovant, Inc. (NASDAQ:IMVT)Norges Bank acquired a new position in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 637,947 shares of the company's stock, valued at approximatelyApril 9, 2025 | marketbeat.comRaymond James Financial Inc. Makes New $505,000 Investment in Immunovant, Inc. (NASDAQ:IMVT)Raymond James Financial Inc. purchased a new stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 20,382 shares of the company's stock, valued at approximately $505April 9, 2025 | marketbeat.comIs Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires?April 8, 2025 | msn.comFranklin Resources Inc. Lowers Holdings in Immunovant, Inc. (NASDAQ:IMVT)Franklin Resources Inc. lowered its position in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 6.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 984,063 shares of the company's stock after selliApril 8, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Shares Bought by Vanguard Group Inc.Vanguard Group Inc. grew its position in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 0.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,679,414 shares of the company's stock after purchasing an additional 20,614 shares duApril 8, 2025 | marketbeat.comRhenman & Partners Asset Management AB Sells 98,000 Shares of Immunovant, Inc. (NASDAQ:IMVT)Rhenman & Partners Asset Management AB decreased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 40.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 145,000 shares of the company's stock after selling 98,000 shares during the periApril 7, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Sees Large Volume Increase - Still a Buy?Immunovant (NASDAQ:IMVT) Sees Strong Trading Volume - Here's WhyApril 4, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Trading Down 5.3% - Time to Sell?Immunovant (NASDAQ:IMVT) Trading Down 5.3% - Time to Sell?April 3, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Sets New 12-Month Low - Here's What HappenedImmunovant (NASDAQ:IMVT) Hits New 12-Month Low - What's Next?April 1, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Shares Sold by Pictet Asset Management Holding SAPictet Asset Management Holding SA trimmed its position in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 4.4% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,175,685 shares of the company's stock after selling 54,624 shares during tApril 1, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Receives Average Rating of "Buy" from BrokeragesShares of Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) have been given a consensus recommendation of "Buy" by the ten analysts that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and oneMarch 30, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Trading 5.3% Higher - Here's WhyImmunovant (NASDAQ:IMVT) Shares Up 5.3% - Time to Buy?March 28, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Shares Down 3.5% - Time to Sell?Immunovant (NASDAQ:IMVT) Shares Down 3.5% - Here's WhyMarch 26, 2025 | marketbeat.comKnights of Columbus Asset Advisors LLC Takes $616,000 Position in Immunovant, Inc. (NASDAQ:IMVT)Knights of Columbus Asset Advisors LLC acquired a new stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 24,873 shares of theMarch 24, 2025 | marketbeat.comLeerink Partners Reaffirms Their Buy Rating on Immunovant (IMVT)March 21, 2025 | markets.businessinsider.comImmunovant (NASDAQ:IMVT) Shares Up 3.9% - Time to Buy?Immunovant (NASDAQ:IMVT) Stock Price Up 3.9% - Here's What HappenedMarch 21, 2025 | marketbeat.comGuggenheim Reiterates "Buy" Rating for Immunovant (NASDAQ:IMVT)Guggenheim reissued a "buy" rating on shares of Immunovant in a research note on Thursday.March 21, 2025 | marketbeat.comBank of America Has Lowered Expectations for Immunovant (NASDAQ:IMVT) Stock PriceBank of America lowered their price objective on Immunovant from $38.00 to $33.00 and set a "buy" rating for the company in a research report on Thursday.March 21, 2025 | marketbeat.comImmunovant price target lowered to $33 from $38 at BofAMarch 21, 2025 | markets.businessinsider.comImmunovant price target raised to $61 from $58 at StifelMarch 21, 2025 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for Immunovant (NASDAQ:IMVT)HC Wainwright reiterated a "buy" rating and issued a $51.00 price target on shares of Immunovant in a research note on Wednesday.March 20, 2025 | marketbeat.comImmunovant data positive for Biohaven, says Deutsche BankMarch 20, 2025 | markets.businessinsider.comImmunovant (NASDAQ:IMVT) Hits New 1-Year Low - Here's WhyImmunovant (NASDAQ:IMVT) Hits New 12-Month Low - Time to Sell?March 20, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Shares Sold by Victory Capital Management Inc.Victory Capital Management Inc. reduced its position in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 86.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,100 shares of the company's stock after sMarch 20, 2025 | marketbeat.comImmunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. WainwrightMarch 20, 2025 | markets.businessinsider.comImmunovant announces results from Phase 3 study of batoclimab in MGMarch 19, 2025 | markets.businessinsider.comImmunovant claims study success for immune disease drug but holds off on submissionMarch 19, 2025 | finance.yahoo.comImmunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going ForwardMarch 19, 2025 | seekingalpha.comImmunovant's muscle drug meets main goal, shares gain on new drug promiseMarch 19, 2025 | msn.comImmunovant will not seek approval for MG therapy, despite hitting endpointsMarch 19, 2025 | finance.yahoo.comRoivant says Immunovant announces results from Phase 3 study of batoclimab in MGMarch 19, 2025 | markets.businessinsider.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)March 19, 2025 | prnewswire.comRoivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.March 19, 2025 | investors.comImmunovant stock falls despite study successMarch 19, 2025 | investing.comImmunovant, Roivant slip after trial data for autoimmune disorder therapyMarch 19, 2025 | msn.comImmunovant's muscle disorder treatment meets main goal in late-stage trialMarch 19, 2025 | reuters.comImmunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) StudiesMarch 19, 2025 | globenewswire.comImmunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ProgramsMarch 18, 2025 | globenewswire.comImmunovant, Inc. (NASDAQ:IMVT) Shares Sold by Skandinaviska Enskilda Banken AB publSkandinaviska Enskilda Banken AB publ trimmed its position in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 60.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 35,316 shares of the company's stock after selMarch 18, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Raises Stock Position in Immunovant, Inc. (NASDAQ:IMVT)Connor Clark & Lunn Investment Management Ltd. raised its holdings in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 29.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 235,884 shares of the company's stock after purchasing an addiMarch 16, 2025 | marketbeat.comAndrew J. Fromkin Sells 8,000 Shares of Immunovant, Inc. (NASDAQ:IMVT) StockImmunovant, Inc. (NASDAQ:IMVT - Get Free Report) Director Andrew J. Fromkin sold 8,000 shares of Immunovant stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $19.60, for a total value of $156,800.00. Following the sale, the director now owns 91,913 shares in the company, valued at $1,801,494.80. This represents a 8.01 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.March 12, 2025 | marketbeat.com Remove Ads Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Email Address IMVT Media Mentions By Week IMVT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMVT News Sentiment▼1.160.78▲Average Medical News Sentiment IMVT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMVT Articles This Week▼146▲IMVT Articles Average Week Remove Ads Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MRNA News Today ASND News Today QGEN News Today VTRS News Today ROIV News Today LNTH News Today RVMD News Today BBIO News Today TGTX News Today LEGN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMVT) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMVT Stock Free IMVT Stock Alerts